Hot Features
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for ma... Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.07 | -4 | 1.75 | 1.79 | 1.5778 | 7538 | 1.73129325 | CS |
| 4 | -0.32 | -16 | 2 | 2.05 | 1.5778 | 6636 | 1.76598168 | CS |
| 12 | -0.02 | -1.17647058824 | 1.7 | 2.4 | 1.56 | 6485 | 1.93992758 | CS |
| 26 | 0.36 | 27.2727272727 | 1.32 | 2.4 | 1.02 | 8751 | 1.70208002 | CS |
| 52 | 0.9147 | 119.521756174 | 0.7653 | 2.4 | 0.697 | 8535 | 1.31911905 | CS |
| 156 | 0.72 | 75 | 0.96 | 3.54 | 0.443325 | 9108 | 1.42781626 | CS |
| 260 | -8.42 | -83.3663366337 | 10.1 | 10.98 | 0.443325 | 8245 | 2.88085087 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.